scispace - formally typeset
L

Lianfeng Zhang

Researcher at Peking Union Medical College

Publications -  109
Citations -  3308

Lianfeng Zhang is an academic researcher from Peking Union Medical College. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 30, co-authored 90 publications receiving 2677 citations. Previous affiliations of Lianfeng Zhang include Chinese Ministry of Health.

Papers
More filters
Journal ArticleDOI

Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates

TL;DR: Peptide-based vaccines against SARS-CoV could be engineered to avoid ADE via elimination of the S597–603 epitope, an alternative strategy to prepare a safe and effective vaccine for ADE of viral infection by identifying and eliminating epitope sequence-dependent enhancement of viral infections.
Journal ArticleDOI

miR-34a, a microRNA up-regulated in a double transgenic mouse model of Alzheimer's disease, inhibits bcl2 translation.

TL;DR: It is shown that the expression of miR-34a is inversely correlated with the protein level of bcl2 in APPswe/PSDeltaE9 mice and age-matched controls, and miR -34a expression directly inhibits bCl2 translation in SH-SY5Y cells.
Journal ArticleDOI

Generating rats with conditional alleles using CRISPR/Cas9.

TL;DR: The application of the CRISPR/Cas9 system is extended and an effective strategy to generate rats with conditional alleles is reported.
Journal ArticleDOI

Genome modification by CRISPR/Cas9.

TL;DR: The CRISPR–Cas9 system has been employed to recruit functional domains that repress/activate gene expression or label specific genomic loci in living cells or organisms, in order to explore developmental mechanisms, gene expression regulation, and animal behavior.
Journal ArticleDOI

MicroRNA-221 inhibits autophagy and promotes heart failure by modulating the p27/CDK2/mTOR axis

TL;DR: The findings reveal that miR-221 is an important regulator of autophagy balance and cardiac remodeling by modulating the p27/CDK2/mTOR axis, and implicate mi R-221 as a therapeutic target in heart failure.